R&D News | pharmaphorum

News

Takeda's Ninlaro fails phase 3 amyloidosis trial

Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.

News

Bayer buys into Arvinas protein degrader discovery platform

Bayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new drugs for cardiovascular and gynaecological diseases and cancer, as well a

Views & Analysis

doctor is sending result of medical test to patient on tablet computer

The importance of virtual trials for patient engagement

How virtual trials help diminish barriers to participation and make clinical research easier for patients.

News

Sanofi names ex-Roche cancer guru Dietmar Berger as developm...

Roche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Amicus expands gene therapy collaboration

Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania have announced a major expansion to their R&D collaboration for gene therapies.

News

BioMarin seeks haemophilia gene therapy approval after promi...

BioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified clinical criteria for regulatory review.

Takeda's Ninlaro fails phase 3 amyloidosis trial

Bayer buys into Arvinas protein degrader discovery platform

The importance of virtual trials for patient engagement

Sanofi names ex-Roche cancer guru Dietmar Berger as developm...

Amicus expands gene therapy collaboration

BioMarin seeks haemophilia gene therapy approval after promi...

Antiviral development in the age of AI: From pre-IND to earl...

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks